Phase 1 dose-escalation study of BI 836909, an anti-BCMA bi-specific 1-cell engager, in relapsed andfor refractory multiple myeloma (RRMM).
- Resource Type
- Journal
- Source
JOURNAL OF CLINICAL ONCOLOGY ; MAY 20 2016, 34 15, 2p. Supplement: S- Subject
- Language
- English
- ISSN
- 15277755